Dissertation on

"A STUDY ON SERUM CHOLINESTERASE AS A BIOMARKER OF LIVER CIRRHOSIS"

Submitted in partial fulfilment for the Degree of

M.D GENERAL MEDICINE

BRANCH – I

INSTITUTE OF INTERNAL MEDICINE

MADRAS MEDICAL COLLEGE

THE TAMIL NADU DR. MGR MEDICAL UNIVERSITY

CHENNAI – 600003

APRIL 2016

CERTIFICATE

This is to certify that the dissertation entitled "**A STUDY ON SERUM CHOLINESTERASE AS A BIOMARKER OF LIVER CIRRHOSIS"** is a bonafide original work done by **Dr. SUJATHA. N**, in partial fulfilment of the requirements for **M.D. GENERAL MEDICINE BRANCH – I** examination of the Tamilnadu Dr. M.G.R Medical University to be held in April 2016, under my guidance and supervision in 2015

Prof. Dr. K.SRINIVASAGALU M.D.,
Director
Guide and Supervisor
Professor of Medicine,
Institute of Internal Medicine,
Madras Medical College & RGGGH,
Chennai – 600003

Prof. Dr. R. VIMALA M.D.,
DEAN
Madras Medical College &
Rajiv Gandhi Government General Hospital
Chennai- 600003

DECLARATION

I hereby solemnly declare that the dissertation entitled "**A STUDY ON SERUM CHOLINESTERASE AS A BIOMARKER OF LIVER CIRRHOSIS"** is done by me at Institute of Internal Medicine, Madras Medical College & Rajiv Gandhi Government General Hospital, Chennai during 2015 under the guidance and supervision of **Prof. Dr. K.SRINIVASAGALU M.D.,** This dissertation is submitted to The Tamilnadu Dr. M.G.R Medical University, Chennai towards the partial fulfilment of requirement for the award of M.D. Degree in General Medicine (Branch I)

Place:
Date:

Dr. SUJATHA. N
Post Graduate Student
M.D. General Medicine,
Institute of Internal Medicine,
Madras Medical College &
RGGGH, Chennai 600003.

ACKNOWLEDGEMENT

I express my heartfelt gratitude to the Dean, **Prof.Dr. R. VIMALA M.D.**, Madras Medical College & Rajiv Gandhi Government General Hospital, Chennai-3 for permitting me to do this study.

I am very grateful to **Prof. Dr. K.SRINIVASAGALU M.D.,** Professor of Medicine, Institute of Internal Medicine, Madras Medical College & Rajiv Gandhi Government General Hospital, Chennai-3 who guided, trimmed my work throughout the period of my study and for his constant support.

I am very much thankful for the help rendered by my Assistant Professors **Dr.D.K.SIVAKUMAR M.D.,** and **Dr. P. BALAMANIKANDAN M.D.,** for their constant help and encouragement.

I am extremely thankful to all the Members of the **INSTITUTIONAL ETHICAL COMMITTEE** for giving approval for my study.

I express my heartfelt gratitude to **Dr.BHARATH RAJ KIDAMBI, Dr.MANOJ KUMAR** and **Dr.M.VELVIZHI** for their constant support and encouragement.

I also thank all the patients who were part of the study and my Professional colleagues for their support and criticisms

CONTENTS

A STUDY ON SERUM CHOLINESTERASE AS A BIOMARKER OF LIVER CIRRHOSIS

ABSTRACT

Background : Serum Cholinesterase is an enzyme which is synthesized by the liver and its level reflects the liver synthetic function .

Methods : Among patients with liver cirrhosis, liver function tests like serum albumin, serum bilirubin,PT INR and serum cholinesterase were done within a week of enrolment.100 patients of liver cirrhosis were studied. The correlation between serum cholinesterase levels and serum albumin, bilirubin, INR, child pugh class and MELD score was studied.

Results: Mean serum cholinesterase levels in Child Pugh class A was 4692.25, B was 2779.68, C was 1892.11. The correlation coefficient between serum cholinesterase and albumin was 0.52, -0.675 with serum bilirubin, -0.49 with INR, -0.85 with Child Pugh class, -0.79 with MELD score, ($p<0.01$).

Conclusions: Serum cholinesterase shows good correlation with serum albumin, serum bilirubin, PT INR, Child Pugh and MELD score. It helps both in the diagnosis of liver cirrhosis and assessing its prognosis.

Keywords: Liver cirrhosis**,** Serum cholinesterase, serum albumin, serum bilirubin, PT INR, Child Pugh class, MELD score.

INTRODUCTION

INTRODUCTION

Hepatic cirrhosis is a commonly encountered clinical entity. Its management includes an array of tests like serum albumin levels, PT INR, serum bilirubin, aminotransferases. Various classification systems have also been developed including the MELD and Child Pugh scores for assessing its severity and prognosis. However, the routinely used tests have certain shortcomings:

- Serum albumin - maybe abnormal due to extrahepatic causes like intestinal malabsorptive states, malnutrition, renal pathologies and secondary to albumin transfusions, thereby interfering with its usage as a marker of liver synthetic capacity and severity of cirrhosis.
- PT INR – abnormal values may occur secondary to vitamin K deficiency, therapeutic anticoagulation, congenital clotting factor deficiencies and its values are altered following fresh frozen plasma transfusions in the treatment of coagulopathy which occurs in decompensated liver disease.
- Serum bilirubin – raised in hemolysis, extrahepatic causes.
- Serum ALP – altered in disoreders of placenta, bone, intestinal mucosa.

- Similarly, aminotransferase, LDH levels can be abnormal secondary to their release from extrahepatic sources following cell membrane damage.

In this regard, serum cholinesterase has been studied as a test of liver function since the early 1950s. It was found that the source of serum cholinesterase is the liver and hence reflects the hepatic function. It can overcome some of the shortcomings of the commonly measured tests of liver function. For instance its values are not affected by albumin or fresh frozen plasma transfusions.

A lot of studies have shown that it helps both in diagnosing liver cirrhosis, in the assessment of its severity and prognosis.

Studies have also shown that it shows good correlation with the routinely performed tests of liver function like serum albumin, PT INR, Child Pugh and MELD scores.

AIMS

AND

OBJECTIVES

AIMS & OBJECTIVES

- To estimate the level of serum cholinesterase in patients with liver cirrhosis

- To compare its level with other tests of liver function like serum albumin, serum bilirubin, PT INR, MELD and Child Pugh scoring.

REVIEW

OF

LITERATURE

REVIEW OF LITERATURE

In 1940 McArdle found that values of serum cholinesterase were very low in patients with liver disease. (5)

In 1952 Andrew Wilson et al reported that the serum cholinesterase values varied significantly in those with liver disease compared with normal subjects and those recovering from liver disease.

They also observed that estimation of serum cholinesterase levels was useful in assessing the liver function recovery , as values returned to normal during recovery.(4)

In 1960 R.G.O. Kekwick noted that the serum cholinesterase values were always very low in chronic liver disease, though the same could not be said of acute liver disease. (3)

CIRRHOSIS OF LIVER

It is a histopathological condition of distortion of the architecture of liver along with regenerative nodule formation. As a consequence there is reduction in the liver mass and liver functions are affected and blood flow inside the liver is affected. This is due to the activation of the stellate cells in the liver leading to deposition of extracellular matrix tissue and collagen.

Though initially cirrhosis was considered to be an irreversible process, it has now been shown that in some instances that when the primary insult leading to cirrhosis is removed, the fibrosis can undergo reversal.

Typical examples include :

Successful treatment – chronic hepatitis C, hemochromatosis

Discontinuation of alcohol use in those with alcoholic liver disease. (2)

BRIEF HISTORY

In 1761 – Gianbattista Morgagni ,the father of anatomic pathology, noted the liver abnormality in the publication of the compliation of his autopsies

In 1826- Laennec gave the term of cirrhosis, meaning orange colour in greek,due to the colour of the liver in cirrhosis.(1)

In 1930-Rossele gave the first theory of pathogenesis of cirrhosis-



Normal microscopic anatomy of liver



The functional unit of the liver is – the acinus

It is roughly triangular in shape. At the base lies the branches of portal vein, bile duct and branches of hepatic artery. This constitutes the Portal triad. At the apex of the acinus lies the terminal hepatic vein.

Zones of the liver parenchyma:

Zone 1 - adjacent to the portal vein

Zone 2-is intermediate zone

Zone 3-adjacent to the terminal hepatic vein

Cords of hepatocytes are radially oriented around the terminal hepatic vein. Vascular sinusoids are present between these cords.

Fenestrated endothelial cells line these sinusoids and form the space of Disse.

Kupffer cells – belonging to the mononuclear phagocyte family are found in this space.

Stellate cells-involved in vitamin A metabolism are found scattered in this space. These are responsible for forming collagen by undergoing transformation into myofibroblast whenever there is liver inflammation.

PATHOGENESIS OF CIRRHOSIS

Normal liver contains type I and type III collagens distributed mainly around the central veins and portal tracts. And type IV collagen forms delicate strands in the space of Disse.

In Cirrhosis- there is lobular deposition of types I and III collagen resulting in septae formation .vascular channels are formed in these septae resulting in blood shunting around liver parenchyma.

Collagen gets deposited in the space of Disse continuously → fenestrations in the endothelial sinusoidal cells are lost → the sinusoidal space no longer serves as a channel in the exchange of solutes between

the plasma and hepatocytes. And the secretion of albumin, coagulation factors by the liver is affected.

Biliary channels → get obliterated → jaundice

Chronic inflammation →Activation of Kupffer cells → cytokine secretion → activation of stellate cells → formation of extracellular matrix , collagen deposition.

Perisinusoidal stellate cells → acquire myofibrils →vascular resistance in the liver increases.

Hepatocytes which remain → regenerate → formation of spherical nodules (6)





NORMAL LIVER



LIVER FIBROSIS

Gross appearance of normal liver



Cirrhotic liver



Thus, Cirrhosis is characterized by:

1. Fibrous septa bridging the portal tracts and the hepatic veins

2. Regenerating nodules surrounded by fibrosis –may be micronodular (<3 mm) or macronodular

3. Architectural disruption of the liver

CAUSES OF CIRRHOSIS

Alcoholism	Chronic viral hepatitis
Cardiac cirrhosis	Inherited metabolic liver disease
Hepatitis B	Hemochromatosis
Hepatitis C	Wilson's disease
Autoimmune hepatitis	α_1 Antitrypsin deficiency
Nonalcoholic steatohepatitis	Cystic fibrosis
Biliary cirrhosis	Cryptogenic cirrhosis
Primary biliary cirrhosis	
Primary sclerosing cholangitis	
Autoimmune cholangiopathy	

Clinical features of cirrhosis(1)

1. Non specific: anorexia ,wasting , easy fatiguability

2. Jaundice

3.Hyperdynamic circulation- flushed peripheries, bounding pulse, increased portal blood flow, decreased renal blood flow

4. Skin changes-

spider nevi

palmar erythema

white nails

5.Clubbing of fingers

6.Endocrine abnormalities:

Hypogonadism → decreased potency, libido,atrophic testes

Gynaecomastia

7.Enlargement of the parotids(alcoholics)

8.Foetor hepaticus

9.Peripheral oedema,Ascitis

10.Bleeding from the GIT

11.Sleep disturbances with or without alterations in the sensorium

12.Hepatic flaps

13.Splenomegaly

Clinical features



COMPLICATIONS OF CIRRHOSIS

Portal hypertension	Coagulopathy
Gastroesophageal varices	Factor deficiency
Portal hypertensive gastropathy	Fibrinolysis
Splenomegaly, hypersplenism	Thrombocytopenia
Ascites	Bone disease
Spontaneous bacterial peritonitis	Osteopenia
Hepatorenal syndrome	Osteoporosis
Type 1	Osteomalacia
Type 2	Hematologic abnormalities
Hepatic encephalopathy	Anemia
Hepatopulmonary syndrome	Hemolysis
Portopulmonary hypertension	Thrombocytopenia
Malnutrition	Neutropenia

PORTAL HYPERTENSION

It is hepatic venous pressure gradient of more than 5 mmhg.

It is due to :

1.Raised intrahepatic resistance to the flow of blood and

2.Vasodilation → increase in the splanchnic blood flow

Pathogenesis of portal hypertension





Gastroesophageal varices:

About 5- 15% of patients with cirrhosis per year → develop varices

1/3 rd of those with varices → bleed

The porto-systemic collaterals



Porto – systemic anastamotic sites in cirrhosis:

Retroperitoneum: *Portal*: Colonic veins *Systemic*: Body wall veins
Lower esophagus: *Portal*: Left gastric veins *Systemic*: Azygos veins
Bare area of liver: *Portal*: Portal veins *Systemic*: Inferior phrenic veins
Umbilicus: *Portal*: Veins of ligamentum teres *Systemic*: Superior and inferior epigastric veins
Upper anal canal: *Portal*: Superior rectal vein *Systemic*: Middle and inferior rectal veins

Factors which predict the risk of bleeding are:

1. Cirrhosis severity as measured by CHILD PUGH score and MELD score
2. Wedged hepatic vein pressure
3. varix size
4. varix location
5. endoscopic stigmata- red wale signs, bluish colour, hematocystic spots, etc.
6. tense ascitis.

Treatment:

1.Primary prophylaxis:

- Involves endoscopic screening → identification of varices at risk of bleeding → band ligation of varices or use of non selective beta blockers

2.Treatment of acute bleed :

- replacement of blood /fluid
- use of stomatostatin and octreotide (50-100 micrograms/hr infusion)
- balloon tamponade using Sengstaken-Blakemore tube/Minnesota tube
- endoscopy - band ligation of varices or sclerotherapy to control acute bleed
- Prevention of further bleed with EVL

3. In patients with variceal hemorrhage which is recurrent treatment involves:

- endoscopic +/- pharmacologic therapy, and once control of bleed is achieved patients with Child's class A can be considered for

surgical shunt or TIPS. And patients with Child's class B or C should be evaluated for transplant, and TIPS should be considered.

ASCITIS

It is the collection of fluid within the peritoneal cavity. The most common cause is cirrhosis due to portal hypertension.

Pathogenesis:

- Cirrhosis → increased intrahepatic resistance→increased portal pressure
- Increased nitric oxide →Splanchnic arterial vasodilation→ increased portal venous inflow

Both lead to increased splanchnic lymph production

- Vasodilation → arterial underfilling → renin angiotensin aldosterone axis activation → sodium retention → accumulation of fluid and extracellular fluid volume expansion → ascitis
- Synthetic function of liver reduced → hypoalbuminemia → reduced oncotic pressure of plasma → leak of fluid into peritoneal cavity

Clinical features:

(i) increase in abdominal girth

(ii) peripheral edema

(iii) dyspnoea when ascitis is massive

(iv) hepatic hydrothorax

Treatment:

- dietary sodium restriction <2 g/day
- diuretics→spironolactone 100-200 mg/day upto 400-600 mg/day,furosemide 40-80 mg/day upto 120-160 mg/day
- Refractory ascitis is presence of ascitis inspite maximal dose of diuretics in patients compliant with a low-sodium diet.
- repeated large-volume paracentesis
- TIPS

Spontaneous bacterial peritonitis

Infection of the ascitic fluid spontaneously presumably due to translocation of the gut flora→to mesenteric lymph nodes → bacteremia →ascitic fluid seeding with bacteria

Most common organisms are : E.coli and other microbial flora.

Streptococcus viridians, staph.aureus and other gram positive bacteria can also be found.

Presence of >2 organisms – suggests SBP due to a perforated viscus

Diagnosis : absolute neutrophil count >250/microliter, cultures

Treatment – 2nd generation cephalosporin-cefotaxim

Prophylaxis against SBP recommended-for patients with UGI bleed,and those recovered from a episode of UGI bleed.

SPLENOMEGALY AND HYPERSPLENISM

It's a complication of portal hypertension.

Hypersplenism is characterized by leucopenia and thrombocytopenia.

No specific treatment is required for splenomegaly.

Splenectomy's done under very rare circumstances.

HEPATORENAL SYNDROME

It is a form of functional renal failure without renal pathology.

Occurs in 10% of advanced cirrhosis patients.

There is renal vasoconstriction alongwith reduced systemic vascular resistance

- Type 1 HRS - significant decrease in creatinine clearance within 1-2 weeks
- Type 2 HRS - rise in serum creatinine which is relatively stable and has a better outcome than type 1 HRS.

Diagnosis – is by exclusion of other etiologies of acute renal failure

International ascitis club criteria for HRS: (2007)

- Liver cirrhosis with ascites
- Serum creatinine concentration >1.5 mg/dL (>133 µmol/L), type I: >2.5 mg/dL
- No lowering of the serum creatinine concentration after at least two days without diuretic treatment and after volume expansion with albumin (recommended dose: 1 g per kg body weight per day, up to a maximum of 100 g/d)
- No evidence of shock
- No treatment with nephrotoxic drugs
- No renal parenchymal changes:
  - no proteinuria >500 mg/day,
  - no microhematuria (>50 RBC),
  - normal configuration of kidneys on ultrasonographic examination

Treatment :

- midodrine,
- octreotide,
- intravenous albumin,
- best treatment being liver transplantation.

HEPATIC ENCEPHALOPATHY

Is an alteration in the patient's mental status and cognitive function in the presence of liver failure.

There is exposure of brain to neurotoxins due to shunting of gut derived neurotoxins along with hepatic insufficiency. Several neurotoxic substances may be involved, this includes :

- ammonia,
- I^3 aminobutyric acid,
- manganese ,
- GABA ,
- mercaptans and
- short chain fatty acids.(7)





The neurologic symptoms can be reversed with the restoration of liver function

Precipitating factors: (8)

- Sepsis-increase in blood ammonia levels with enhanced effect of toxins in CNS
- Gastrointestinal bleed-liver function impairment with rise in blood ammonia levels
- Hypokalemia, azotemia, increased protein intake, dehydration, constipation and diuretics-due to increase in blood ammonia levels

- Acute hepatitis-due to further impairment of liver function by activated cytokines and cytokines may increase blood brain barrier permeability to ammonia.
- Surgery-due to hepatic hypoperfusion
- Psychoactive drugs - by activation of inhibitory neurotransmission

Clinical features: (9)

- Alterations in consciousness-sleep disturbances in the form of hypersomnia initially, with later reversal of normal sleep pattern , slowness of responses , apathy, delirium.
- Personality changes – irritability, lack of concern for others.
- Intellectual deterioration – visuo spatial disturbances detected as constructional apraxia, confusion, difficulty writing.
- Speech – monotonus with slowness, slurring, dysphasia
- Fetor hepaticus due to lung excretion of mercaptans. However does not have any correlation with the duration or degree of encephalopathy.
- Flapping tremor or asterixis - due to defective inflow of afferent information to the reticular formation of brainstem leading to lapses in posture. It is demonstrated by outstretching of patients arms and separation of fingers or hyperextension of wrists. There is

flexion extension movements occurring at the metacarpophalangeal joints and wrists alongwith movements of the digits laterally.

Flapping tremors



Semiquantitative grading of mental status in hepatic encephalopathy using the West Haven criteria (modified from Conn et al. [e32]). Grade 0 corresponds to MHE.

	Level of consciousness	Neuropsychiatric symptoms	Neurological symptoms
Grade 0 = MHE	Normal	Impairments only measurable with psychometric tests	None
Grade 1	Slight mental slowing down	Eu-/dysphoria, irritability and anxiety, shortened attention span	Fine motor skills disturbed (impaired ability to write, finger tremor)
Grade 2	Increased fatigue, apathy or lethargy	Slight personality disorder, slight disorientation to time and place	Flapping tremor, ataxia, slurred speech
Grade 3	Somnolence	Aggression, marked disorientation to time and place	Rigor, clonus, asterixis
Grade 4	Coma	–	Signs of increased intracranial pressure

MHE, minimal hepatic encephalopathy

Treatment : (2)

1. Treatment of precipitating factors

2. Lactulose – leads to colonic acidification , catharsis → nitrogenous waste product elimination from the gut. Dose titrated to result in 2-3 soft stools/day.

3. Poorly absorbed antibiotics like metronidazole and neomycin.

4. Rifaximin 550 mg twice daily.

5. Zinc supplementation.

PULMONARY COMPLICATIONS: (10)

(i) **Hepato pulmonary syndrome**- vasodilation of pulmonary microvasculature → hypoxemia.

Clinical features:

Platypnoea- dyspnoea in upright posture due to vasodilation at the lung base with blood shunting through the base in the upright posture→hypoxemia

Clubbing of the digits, spider angioma and cyanosis.

Treatment: the only proved treatment is liver transplantation.

Intrapulmonary vasodilation occurring in HPS:



(ii) **Portopulmonary hypertension**- vascular remodeling → increased pulmonary vascular resistance → raised mean pulmonary artery pressure (>25 mm hg)

Clinical features:

- Nonspecific. Most common is progressive eexertional dyspnoea, syncope, edema of the peripheries, chest pain.
- JVP maybe raised with a loud second heart sound-pulmonary component and a systolic murmur due to tricuspid regurgitation.

Treatment of portopulmonary hypertension:

- Vasodilators (can reverse the vasoconstriction but almost no effect on the fibrotic remodeling changes).
- Diuretics.
- Prostacyclin (epoprostenol) (64,65,66) -vasodilator and inhibitor of platelet aggregation.
- Bosentan (67, 68), Ambrisentan – endothelin receptor antagonists
- Inhalation of nitric oxide.
- L-arginine.
- Phosphodiesterase inhibitors. (69)
- Orthotopic liver transplantation – not curative, indicated in only selected patients who improve clinically after medical therapy. (70)

CARDIAC CHANGES IN CIRRHOSIS

- Circulation is hyperdynamic in patients with liver cirrhosis.
- Peripheral vascular resistance is reduced and so is arterial BP.
- Cardiac output is raised.
- They also have prolonged QTc.(22)
- Cirrhotic cardiomyopathy characterized by:

➢ Systolic dysfunction with

✓ ejection fraction in the resting state <55%

- ✓ reduced increase in cardiac output during exercise, states of change in volume or with pharmacologic stress.

- Diastolic dysfunction with
  - ✓ E/A ratio <1.0 (ratio of early to late ventricular filling velocity).
  - ✓ prolongation of isovolumetric relaxation time and also the deceleration time.

- Electrophysiological changes

Mechanism of cirrhotic cardiomyopathy:




Cirrhosis and portal hypertension
Arterial vasodilatation
RAAS↑
SNS↑
SVR↓
HR↑
CO↑
Central hypovolaemia
hyperdynamic circulation
Hepatorenal
syndrome
Cirrhotic
cardiomyopathy
Hepatopulmonary
syndrome

MALNUTRITION :

Cirrhosis is a catabolic state assosciated with metabolism of muscle protein.

Factors contributing to malnourishment in cirrhotics include decreased dietary intake, alterations in protein metabolism and decreased nutrient absorption from the GIT.

Treatment : dietary supplementation.

COAGULOPATHY:

Decrease in the synthesis of vitamin K dependent coagulation factors, and decreased clearance of anti coagulants

They may also suffer from thrombocytopenia as a result of hypersplenism and abnormalities of platelet function.

Treatment :

- Desmopressin – may improve bleeding time and activated partial thromboplastin time but does not affect prothrombin time. (71)
- Vitamin K – to optimize gamma carboxylation of factors dependent on vitamin K. (72)
- Fresh frozen plasma – In cases of bleeding due to clotting factor deficiencies.

BONE DISEASE:

There is increased bone resorption in cirrhotics →leading to bone loss.

Treatment: bisphosphonates if there is decreased bone mass in DEXA scan.

HEMATOLOGIC ABNORMALITIES:

Neutropenia, macrocytosis and anemia due to hypersplenism, iron deficiency, hemolysis and deficiency of folate.

INVESTIGATIONS:

1. Complete blood count : (11)

- Leucopenia
- thrombocytopenia
- anaemia

2.PT INR – raised in caogulopathy.

3.Liver function tests: (12)

- bilirubin→normal in compensated cirrhosis
- serum albumin→decreased
- globulins→increased

- reversal of albumin - globulin ratio
- moderate rise in aspartate aminotransferase (AST) and alanine aminotransferase (ALT)
- alkaline phosphate raised-more in primary sclerosing cholangitis and primary biliary cirrhosis
- raised gamma glutamyl transpeptidase (GGT) – alcohol induced liver disease

4. Renal function tests:

- Serum creatinine - raised in hepato renal syndrome
- Serum sodium levels- hyponatremia – correlates with disease severity

5. Ultrasound abdomen shows: (13,14)

- Shrunken liver
- nodular surface
- increase in the liver echoes

6. Fibroscan helps assess the severity of fibrosis

7. Liver biopsy (15) - has sensitivity of 80-100 %, is the confirmatory test.

The traditional liver function tests

Routinely peformed liver function tests include : (50)

Tests of liver synthetic function:

1.SERUM ALBUMIN:

Amount of albumin secreted by the liver per day is around 10 grams.

Normal level: 3.5 – 5.0 g/dL

When there is hepatocellular injury or damage the ability of the liver to synthesis albumin is reduced leading to hypoalbuminemia.

However levels of serum albumin can also be reduced in conditions such as :

- enteropathy,
- malnutrition,
- kidney diseases and
- hormonal disturbances.

Thus hypoalbuminemia does not necessarily indicate hepatic dysfunction.

The half life of albumin is around 20 days hence not useful in assessing hepatic synthetic function in acute liver disease.

But it can be used for assessing the prognosis in chronic liver disease.

Pre albumin is also synthesized by liver but its half life is shorter.

Several extrahepatic factors influence its levels hence it is not used for assessing liver dysfunction.

2.PROTHROMBIN TIME:

The liver synthesizes all the clotting factors except factor VIII which is synthesized by reticuloendothelial cells and endothelium of the vessels.

Prothrombin time is a measure of the production rate of thrombin from prothrombin.

This is dependent on factors II, VII, IX, X which are essential for thrombin generation. And these are produced in the liver. Thus prothrombin time is a measure of hepatocyte synthetic function.

Normal value – 10.9-12.5 seconds

The three pathways that makeup the classical blood coagulation pathway



But, prothrombin time can also be increased in the following conditions:

- vitamin K deficiency,
- therapeutic use of anti coagulants,
- in states of consumptive coagulopathy like disseminated intravascular coagulation,
- congenital clotting factor deficiencies.

In liver disease when prothrombin time is prolonged, factor VIII levels are increased or normal but in DIC, levels of factor VIII are reduced.

Prothrombin time helps assess the hepatic synthetic function both in patients with acute and chronic liver disease.

The international normalized ratio (INR) has been used to standardize anticoagulation therapy monitoring and is used in the MELD and Child Pugh scoring systems.

Normal value 0.9-1.2

Role of vitamin K:

It is essential for gamma carboxylation of the clotting factors II, VII, IX, X and their normal functioning.

Vitamin K deficiency can be due to:

- malnutrition

- antibiotic usage

- malabsorptive states

Use of warfarin affects vitamin K induced gamma carboxylation

Tests of hepatocellular necrosis and excretory functioning of liver:

1. **AMINOTRANSFERASES:**

This includes Aspartate aminotransferase (AST,otherwise called serum glutamic oxaloacetic transaminase [SGOT] and alanine aminotransferase(ALT, otherwise called serum glutamic pyruvic transaminase [SGPT]).

ALT is predominantly found in the liver, in the cytoplasm.

But, AST is found in a number of extrahepatic sites like skeletal muscle, brain, kidneys, myocardium, pancreas, RBC s, in the cytoplasm and mitochondria.

Values of these enzymes correlate with the body mass index.

Normal values:

ALT	10 – 55 U/L
AST	10 – 40 U/L

Raised levels of these enzymes suggest hepatocellular injury.

In patients with inappropriately elevated AST levels (disproportionate to the ALT levels), extrahepatic origin of this enzyme must be excluded.

However, in severe rhabdomyolysis levels of both these enzymes are high.

However, elevated levels of serum aminotransferases correlate poorly with severity of liver damage or injury and is also not a good predictor of the outcome in liver disease.

Values can be normal even in patients with advanced liver cirrhosis.

Azotemia can cause a falsely low serum levels of AST.

AST can also rarely form a complex with albumin leading to persistently raised serum AST levels.

AST/ALT ratio:

- Alcoholic hepatitis – ratio is >2
- Cirrhosis secondary to liver disease of any etiology – ratio >1
- NASH (nonalcoholic steatohepatitis) in the absence of cirrhosis– ratio less than or equal to 1

- Wilson s disease – may have ratio even graeter than 4 in fulminant cases.

2. LACTATE DEHYDROGENASE:

Found in a wide variety of tissues like liver, myocardium, RBC s, skeletal muscle, kidneys and brain.

Levels are raised in ischemic hepatitis and in malignant infiltrations of liver.

Markers of cholestasis

1. ALKALINE PHOSPHATASE:

Non specific – found in bone, kidney, intestine, WBC s, placenta.

Half life is 5 - 7 days

Normal level : 45 – 115 U/L

Levels are raised in active metabolic states eg.pregnancy, adolescence.

Raised values are also found in the following states:

- chronic renal failure
- biliary obstruction

- primary liver malignancies
- liver secondaries

"Regan isoenzyme" – ALP levels raised in patients with malignancy but without bone/ liver involvement.

"Bystander phenomenon"- values are raised as a result of non specific hepatitis in Hodkin's disease and renal malignancies but without direct liver involvement.

2. GAMMA GLUTAMYL TRANSPEPTIDASE(GGTP) :

It is a microsomal enzyme.

Found in hepatocytes, biliary epithelium, kidney, heart, pancreas, lung, brain and spleen.

Normal level : 0 – 30 U/L

Values are raised in cholestasis and a GGTP/ALP ratio of >2.5 suggests alcohol use.

3. 5′-NUCLEOTIDASE (5′NT):

Found in liver, pancreas, blood vessels, myocardium and brain.

In liver it is found in canalicular and sinusoidal plasma membranes.

Normal value: 0 – 11 U/L

Values are raised in cholestatic liver disease

Values lag behind the elevations of GGTP and ALP.

4. BILIRUBIN

It is the breakdown product of catabolism of hemoglobin.

Normal value: 0.0 – 1.0 mg/dL

Pathway showing generation of bilirubin:



Normal value is < 1 mg/dL

It is fractionated into direct and indirect bilirubin:

DIRECT BILIRUBIN	INDIRECT BILIRUBIN
Also called conjugated bilirubin	Called unconjugated bilirubin
Water soluble	Lipid soluble
Excreted in urine	Excreted by the biliary system
Makes up less than 10%	Makes up more than 90% of total bilirubin

Levels of indirect bilirubin are raised in:

- hemolysis
- hematoma resolution
- ineffective erythropoiesis
- injury to muscles

Levels of direct bilirubin are increased in:

- hepatobiliary diseases

Conjugated hyperbilirubinemia cannot differentiate parenchymal liver disease from biliary obstruction.

Serum bilirubin indicates prognosis in the following conditions:

- liver cirrhosis
- acute liver failure
- primary biliary cirrhosis
- alcoholic hepatitis

It is incorporated into the MELD and Child Pugh scoring systems

In long standing cholestasis, a fraction of conjugated bilirubin remains tightly bound to albumin which prevents its excretion in urine and this responsible for the persistence of hyperbilirubinemia inspite of cholestasis recovery.

This is named the delta fraction.

5. BILE ACIDS

Produced from cholesterol in the hepatocytes

Not routinely used as a test of liver function.

Prognostic scores used in liver cirrhosis:

1.Child Turcotte Pugh classification (CTP)

2.Model for End stage Liver Disease(MELD)

1. **Child Turcotte Pugh score**: (50)

Predicts prognosis following surgery

Initially designed to predict prognosis of patients about to undergo portosystemic shunt surgery due to liver disease.

Also gives information about the frequency of complications occurring post-operatively like hepatic encephalopathy, intractable ascitis, renal failure, gastrointestinal bleeding and worsening of liver functions.

Child-Turcotte-Pugh Classification for Severity of Cirrhosis			
Clinical and Lab Criteria	Points*		
	1	2	3
Encephalopathy	None	Mild to moderate (grade 1 or 2)	Severe (grade 3 or 4)
Ascites	None	Mild to moderate (diuretic responsive)	Severe (diuretic refractory)
Bilirubin (mg/dL)	< 2	2-3	>3
Albumin (g/dL)	>3	3-3.5	<3
Prothrombin time			
Seconds prolonged	<4	4-6	>6
International normalized ratio	<1.7	1.7-2.3	>2.3
*Child-Turcotte-Pugh Class obtained by adding score for each parameter (total points)			
Class A = 5 to 6 points (least severe liver disease)			
Class B = 7 to 9 points (moderately severe liver disease)			
Class C = 10 to 15 points (most severe liver disease)			



Child Pugh classes and their surgical outcomes: (51, 52)

Class A – well compensated cirrhosis:

- Moderate increase in surgical risk

Class B and C – decompensated cirrhosis:

- Substantial increase in surgical risk.
- Complications should be treated before elective surgery.
- In Child class C surgery must be done only in life threatening conditions eg. incarcerated hernia.
- In patients undergoing surgery, meticulous care is essential. This includes:

✓ Improvement in general nutritional status

- ✓ Hemodynamic stability maintenance
- ✓ Broad spectrum antibiotic therapy
- ✓ Coagulopathy correction
- ✓ Avoiding nephrotoxins
- ✓ Avoiding sedatives – to avoid precipitating hepatic encephalopathy

2.Model for End stage Liver Disease(MELD):

It is based on serum bilirubin, serum creatinine levels and INR values.

It is used to allocate grafts for hepatic transplantation.

Has many advantages over the CTP scoring system and used to predict early mortality following TIPS – transjugular intrahepatic portosystemic shunt. (53,54)

MELD = 3.78 x $\log_e$ serum bilirubin (mg/dL) +
11.20 x $\log_e$ INR +
9.57 x $\log_e$ serum creatinine (mg/dL) +
6.43 (constant for liver disease etiology)

Ranges between 6 and 40.

Advantages of MELD scoring system over CTP scoring:

- Variables in CTP lack reproducibility and consistency
- prone to subjective variations – ascitis, hepatic encephalopathy graded subjectively
- patients are classified only into three categories
- expected survival is not quantified
- patients with severe decompensation are not quantified.

MELD overcomes these problems and is a more reliable prognostic indicator.



Additional tests :

For assessment of liver function and severity of liver injury includes:

ULTRASOUND ELASTOGRAPHY:

It makes use of the fact that the velocity of transmission of shear waves is altered by liver fibrosis (stiffness).

The waves are created by a vibratory source. (55)

The stiffness measured correlates with the stage of fibrosis of liver. (56)

However difficult to use when patients are obese. (57)

Values >12.5 kPa indicate liver cirrhosis (58)

However, fibrosis can be overestimated in those with extrahepatic cholestasis or acute liver injury. (59,60,61)



Quantitative tests of liver function:

- Indocyanine green clearance
- Galactose elimination capacity
- Aminopyrine breath test
- Antipyrine clearance
- Monoethylglycinexylidide (MEGX)
- Caffeine clearance

However these tests have limitations including issues about: (62,63)

- Cost
- Availability
- Lack of validity
- Invasiveness

LIVER BIOPSY

Indicated for:

- Finding the liver disease cause and for
- Finding the extent of damage to the liver

Pre-requisites:

- INR value should not be greater than 3 after giving 10 mg of vitamin K by intramuscular route.

- Platelet count must be >50,000.

Techniques:

- Aspiration with Menghini needle
- Transjugular liver biopsy
- USG or CT guided biopsy
- Tru cut needle biopsy

Complications of biopsy: (73)

- Pleurisy
- Fibrinous perihepatitis
- Haemorrhage
- Intrahepatic hematomas
- Haemobilia
- Arteriovenous fistula
- Biliary peritonitis
- Puncturing of other organs
- Infections

Percutaneous liver biopsy



Tru-cut biopsy needle



Transjugular liver biopsy



SERUM CHOLINESTERASE

Cholinesterases are basically enzymes that have been classified into two types by Mendel and Rudney as:

- acetyl cholinesterase, otherwise called “true” cholinesterase → this is present in glial tissues and red blood cells.
- serum or butryl or succinyl cholinesterase, otherwise called “pseudo” cholinesterase → which is synthesized by the liver. (16)

Cholinesterases basically catalyze the hydrolysis of acetylcholine, which is a neurotransmitter, into acetic acid and choline.(30)



This reaction is essential for the return of a cholinergic neuron to its resting state following its activation.(31)

ACETYL CHOLINESTERASE

Acetylcholine(Ach) acts as a neurotransmitter at the nerve terminals.

When an action potential reaches the nerve terminal Ach is released and acts on the post synaptic Ach receptor to result in transmission of nerve signal.

Here, acetyl cholinesterase catalyzes Ach hydrolysis into choline and acetate thereby terminating the action of Ach.

Acetyl cholinesterase occurs in a tetrameric G4 form mostly in the mammalian brain, and the amounts of the monomeric G1 form are much lesser.

It is found in red blood cells , central and peripheral nervous system and in muscles.

It has the following properties: (32)

- high turnover
- high affinity for acetylcholine
- low affinity for non choline esters
- gets inhibited when concentrations of acetylcholine are high.

SERUM CHOLINESTERASE ("pseudo" CHOLINESTERASE)

It is an alpha glycoprotein with the following characteristics:

- lower affinity for acetylcholine
- high concentrations of acetylcholine do not inhibit it.(32)
- half life is 12 days (33,34)
- levels are raised in:
  - ✓ diabetes,
  - ✓ hyperthyroidism,
  - ✓ uremia,
  - ✓ hyperlipidemia. (35-37)
- levels are lowered in:
  - ✓ protein energy malnutrition (38)
  - ✓ chronic liver damage and cirrhosis
  - ✓ European studies show that there is a prevalence of about 3-4% of congenital serum cholinesterase deficiency.(39)

Assessment of serum cholinesterase in various physiological and pathological conditions

1. In protein energy malnutrition – eg. marasmus and kwashiorkor levels are low, however rise with nutritional rehabilitation.(40,41)

This is probably due to inadequate substrate availability rather than hepatic failure. (32)

2. There was not any significant correlation between serum cholinesterase levels and old age in a study done by Lidia S et al.

3. Levels were found to be low in patients with hepatic metastases even though other liver functions were normal.(43)

This could be due to the anorexia accompanying malignancy. (44)

Bozzeti et al. noted that levels of serum cholinesterase, body weight, thyroxin- binding prealbumin, transferrin, retinol binding protein and nitrogen balance increased following nutritional supplementation in patients with cancer. (45)

4. Patients on hemodialysis are often malnourished and depleted of proteins, and as a result of the catabolic state values of serum cholinesterase and albumin were found to be low. (46)

5. In severely burnt and critically ill patients values of serum cholinesterase were found to be reduced suggesting abnormal liver biosynthesis.(47)

6. In patients with anorexia nervosa, lower activity of serum cholinesterase has been reported suggesting decreased nutrient availability. (48)

7. In AIDS patient with an abnormal D-xylose test the values of serum cholinesterase, albumin and serum total proteins were found to be significantly lower than those who had normal D-xylose test. (49)

ASSESSMENT OF SERUM CHOLINESTERASE LEVELS IN PATIENTS WITH LIVER DISEASES

McArdle was the first to suggest that estimating serum cholinesterase was useful in distinguishing post hepatic from hepatic jaundice.(5)

It originates from the liver and is associated with albumin synthesis closely. (17,18,19)

Serum cholinesterase levels improve following successful liver transplant – thereby the origin of serum cholinesterase from the liver is confirmed. (20)

It has also been observed that normalization of serum cholinesterase values may indicate the earliest point of recovery in liver injury. (21)

It is also found that in cases of extra-hepatic obstruction secondary to malignancies , the values of this enzyme are low probably due to either malnutrition or impaired liver function.(23,24,25)

M.G. Khan noted in his study that estimation of serum cholinesterase was useful in both diagnosis and prognosis of cirrhosis of the liver. (26)

Andrew Wilson et al observed that the serum cholinesterase levels in patients with liver disease was significantly different from the normal patients and those recovering from liver injury.

They too reported that serum cholinesterase estimation was useful in confirming impairment of liver function and also as a prognostic indicator of liver function recovery

Their studies also revealed that:

- The values of this enzyme were normal in extrahepatic biliary obstruction which was of short duration and
- values were low in attacks of cholangiohepatitis, malignant disease and prolonged extra hepatic obstructions.(27)

Hunt and Lehmann evaluated the role of estimating serum cholinesterase in the prediction of outcomes of portal venous shunt surgeries.(28)

Apart from cirrhosis of liver, studies have suggested that estimating serum cholinesterase can also be useful in facilitating earlier diagnosis of non alcoholic fatty liver in patients with type 2 diabetes mellitus.(29)

MATERIALS

AND

METHODS

MATERIALS AND METHODS

SOURCE OF DATA:

Patients who were admitted in the Institute of Internal Medicine, Madras Medical College and Rajiv Gandhi Government General Hospital, Chennai-3 and diagnosed with liver cirrhosis, with fulfillment of the inclusion criteria and exclusion criteria were included in the study.

SAMPLE SIZE: 100

STUDY DESIGN:

Hospital based observational study

STUDY DURATION:

6 months: March 2015 – August 2015

INCLUSION CRITERIA:

- Cases diagnosed with liver cirrhosis clinically and by ultrasonography.

EXCLUSION CRITERIA

- Organophosphate, carbamate poisoning
- Exposure to succinyl choline, cocaine, codeine and morphine.

- Albumin or blood transfusion 4 weeks prior to enrolment in the study
- History of or clinical evidence of UGI bleed at the time of enrolment in the study
- Liver transplanted individuals

DATA COLLECTION AND METHODS:

Sampling method used was purposive. After selection, patients were subjected to thorough history taking and clinical examination. Following investigations were performed:

- Liver function tests
- Complete blood count
- Renal function tests
- Viral markers
- PT INR
- Ultrasonography of the abdomen
- Serum cholinesterase

ANALYSIS OF SERUM CHOLINESTERASE:

The assay for serum cholinesterase was done using propionylthiocholine as substrate, by the kinetic propionylthiocholine method.

The reagents used included – propionylthiocholine, 2-nitrobenzoic acid, buffer and stabilizers.

Cholinesterase caused the hydrolysis of propionylthiocholine to propionic acid and thiocholine. This thiocholine reacted with 2-nitrobenzoic acid to result in the formation of 5-thio-2-nitrobenzoic acid, which is yellow in colour.

Fresh and non hemolysed serum was used for the assay.

About 20 microliters of the sample was used with 1 ml of the reagent and the and the absorbance was first read at 15 seconds and then at 45 seconds and the results were calculated by the instrument automatically using the following formula:

Activity in U/L = Absorbance/30 seconds × factor

Factor = [TV×1000×2] ÷ [14.64 × SV × P]

Where:

TV= total reaction volume in ml

SV= sample volume in ml

14.64= millimolar absorption coefficient of 5-thio-2-nitrobenzoic acid at 405 nm.

P=cuvette pathlength in cm

2=conversion from absorbance/second to absorbance/minute.

The normal values at 37 degree Celsius: 4900 – 11900 U/L.

MELD SCORE - The calculator in the UNOS website was used to calculate MELD scores.

Ascitis - detected clinically and by ultrasonography

Hepatic encephalopathy- was graded clinically

The correlation between the values of serum cholinesterase and the following variables was studied:

- Serum albumin
- Serum bilirubin
- INR
- Child Pugh score
- MELD score

STATISTICAL METHODS USED:

The data was analysed using SPSS software. Pearsons correlation coefficient and p value were calculated to find the statistical significance. Variables were considered to be significant if p value <0.05.

OBSERVATION

AND

RESULTS

OBSERVATION AND RESULTS

Table 1. AGE DISTRIBUTION

Age Group	Frequency	Percentage
20-30	6	6
31-40	30	30
41-50	40	40
51-60	18	18
>60	6	6
Total	100	100

Most cases of cirrhosis (40 patients) occur in the 41 – 50 years age group (40%)



Table 2. SEX DISTRIBUTION

Sex	Frequency	Percentage
MALE	80	80%
FEMALE	20	20%
Total	100	100%



Among the 100 patients in our study, 80 patients (80%) were males and 20 patients (20%) were females

Table 3. ETIOLOGY OF CIRRHOSIS

Etiology	Frequency	Percentage
Alcohol	68	68
Alcohol+HbSAg positive	3	3
Alcohol+HCV	2	2
HbSAg positive	6	6
HCV	2	2
Others	19	19
Total	100	100



The most common cause for cirrhosis among the patients in our study was alcohol, seen in 68 patients (68%).

Table 4. DISTRIBUTION OF ASCITIS

Ascites	Severity	Frequency		Percentage
NO		17		17
YES	Mild-Moderate	70		
	Severe	13	83	83
Total			100	100



In our study 83 patients (83%) presented with ascitis, and among them 13 patients (13%) had severe (i.e. poorly controlled ascitis) and 70 patients (70%) had mild – moderate (easily controlled ascitis).

Table 5. DISTRIBUTION OF ICTERUS

	Frequency	Percentage
No	28	28
YES	72	72
Total	100	100



In our study, 72 patients (72%) presented with icterus while the remaining patients did not have icterus clinically.

Table 6. DISTRIBUTION OF HEPATIC ENCEPHALOPATHY

Present	Grade	Frequency	Percentage
YES	Gr I	10	10
	Gr II	13	13
	Gr III	7	7
	Gr IV	1	1
NO		69	69
Total		100	100



In our study, 31 patients (31%) presented with hepatic encephalopathy, of which 10 patients were in grade I (10%), 13 patients (13%) in grade II, 7 patients (7%) in grade III and 1 patient (1%) in grade IV.

Table 7. DISTRIBUTION OF SPLENOMEGALY

	Frequency	Percentage
YES	63	63
NO	37	37
Total	100	100



In our study, 37 patients (37%) had splenomegaly, as detected by ultrasonography.

Table 8. BILIRUBIN RANGE

Bilirubin Range	Frequency	Percentage
<2	17	17
2 to 3	12	12
>3	71	71
Total	100	100



In our study, 71 patients (71%) had bilrubin levels greater then 3 mg/dl, 12 patients (12%) had bilirubin levels between 2 to 3 mg/dl and 17 patients (17%) had bilirubin levels less than 2 mg/dl.

Table 9. INR RANGE

INR Range	Frequency	Percentage
<1.7	73	73
1.7-2.3	21	21
>2.3	6	6
Total	100	100



In our study, 73 patients (73%) had INR levels less than 1.7, 21 patients (21%) had values between 1.7 – 2.3 and 6 patients (6%) had values >2.3

Table 10. CHILD PUGH CLASS DISTRIBUTION

CPC	Frequency	Percentage
A	24	24
B	41	41
C	35	35
Total	100	100



In our study, 41 patients (41%) belonged to Child Pugh class B, 35 patients (35%) belonged to Child Pugh class C and 24 patients (24%) belonged to Child Pugh class A.

Table 11. MELD SCORE DISTRIBUTION

MELD Range	Frequency	Percentage
<=15	36	36
>15	64	64
Total	100	100



In our study, 64 patients (64%) had MELD score greater 15 and 36 patients (36%) had a MELD score less than or equal to 15.

Table 12. CORRELATION BETWEEN SERUM ALBUMIN AND SERUM CHOLINESTERASE

Serum Albumin	S.che Mean	Min	Max	Std	Range	Correlation	P Value
>3.5	4360.269231	1437	6101	1053.098	4664	0.52124	<0.01
3-3.5	2531.509434	1237	5125	815.0791	3888		
<3	2155.619048	1437	4800	756.957	3363		



In our study, serum albumin levels were compared with the serum cholinesterase levels. It was found that the serum cholinesterase levels were lower in patients with lower values of serum albumin (positively correlated) which was statistically significant with p – value < 0.01.

Table 13. Correlation between Serum Bilirubin and Serum Cholinesterase

Bilirubin Range	Frequency	Percentage
<2	17	17
2 to 3	12	12
>3	71	71
Total	100	100

	Serum Cholinesterase					
Bilirubin Range	**Mean**	**Min**	**Max**	**Range**	**Correlation**	**P Value**
<2	4567.2353	2131	6101	3970	-0.675	<0.01
2 to 3	4361.4167	2963	5318	2355		
>3	2293.3099	1237	4396	3159		



In our study, serum bilirubin levels were negatively correlated with serum cholinesterase levels and the p value was <0.01 % which was statistically significant.

Table 14. CORRELATION BETWEEN INR (INTERNATIONAL NORMALISED RATIO) AND SERUM CHOLINESTERASE

INR Range	Frequency	Percentage
<1.7	73	73
1.7-2.3	21	21
>2.3	6	6
Total	100	100

	Serum Cholinesterase					
INR Range	Mean	Min	Max	Range	Correlation	P Value
<1.7	3297.438	1237	6101	4864	-0.49565	<0.01
1.7-2.3	1998.286	1437	4296	2859		
>2.3	1688	1356	1967	611		



In our study, it was found that INR value was negatively correlated with the values of serum cholinesterase and it was statistically significant with p value <0.01.

Table 15. CORRELATION BETWEEN CHILD PUGH CLASS AND SERUM CHOLINESTERASE

	Serum Cholinesterase				Correlation	P Value
CPC	**Mean**	**Min**	**Max**	**Range**		
A	4692.25	3845	6101	2256	-0.850087	<0.01
B	2779.682927	1852	4800	2948		
C	1892.114286	1237	2649	1412		



In our study, it was found that serum cholinesterase values were higher among Child Pugh class A patients than class B patients, in whom the values of serum cholinesterase were higher than class C patients. Thus, higher Child Pugh grading correlated negatively with the serum cholinesterase values and it was statistically significant with p value <0.01

Table 16. CORRELATION BETWEEN MELD SCORE AND SERUM CHOLINESTERASE

	Serum Cholinesterase					
MELD Score	**Mean**	**Min**	**Max**	**Range**	**Correlation**	**P Value**
<=15	4304.833	2131	6101	3970	-0.7927219	<0.01
>15	2153.609	1237	3125	1888		



In our study, it was found that MELD scores were inversely correlated with the serum cholinesterase levels and it was statistically significant p value <0.01.

DISCUSSION

DISCUSSION

Our study was conducted to estimate the levels of serum cholinesterase among patients with liver cirrhosis and compare its level with other tests of liver function like serum albumin, serum bilirubin, PT INR and compare it with MELD and Child Pugh scores.

Our study population consisted of 100 patients who were diagnosed with cirrhosis of liver either by ultrasonography or clinically. Serum cholinesterase levels were measured in all the 100 patients along with routinely performed tests like serum bilirubin, serum albumin, PT INR, serum creatinine.

Analysis was done to study the correlation between levels of serum cholinesterase and levels of serum albumin, serum bilirubin, INR and severity of cirrhosis of liver using Pearson's correlation coefficient. Following observations were made from our study.

Age distribution:

Out of 100 patients, majority were in the 41 – 50 years age group (40%) . This showed that cirrhosis is most commonly seen in the middle age.

Sex distribution:

Out of 100 patients, 80 patients were males (80%) and the remaining 20 patients (20%) were females. The male to female ratio is 4:1.

Etiology

Among 100 patients with liver cirrhosis, the most common etiological cause for cirrhosis was alcohol in 68 patients (68%) followed by other causes in 19 patients (19%).

Clinical signs:

Out of the 100 patients in the study, 83 patients (83%) had ascitis, 72 patients (72%) had icterus,63 patients (63%) had splenomegaly and 31 patients (31%) had hepatic encephalopathy.

Among patients with ascitis, 70 patients (70%) had mild – moderate (medically controlled) ascitis and the remaining 13% had severe ascitis (medically refractory)

Among the 31 patients with hepatic encephalopathy, 10 patients (10%) had grade I, 13 patients (13%) had grade II, 7 patients (7%) had grade III, 1 patient (1%) had grade IV hepatic encephalopathy.

Among the 100 patients, 63 patients (63%) had splenomegaly which was indicative of the presence of portal hypertension.

Bilirubin levels:

Among the 100 patients, 71 patients (71%) had a bilirubin level greater than 3 mg/dl and 12 patients (12%) had bilirubin levels between 2 to 3. A bilirubin level equal to or greater than 3 can be detected clinically as scleral icterus.

Coagulopathy:

In our study, 73 patients (73%) had INR levels less than 1.7. Thus the majority of patients in our study did not have coagulopathy.

Child-Pugh class:

In our study, out of 100 patients, 41 patients (41%) belonged to class B, 35 patients (35%) to class C and 24 patients (24%) belonged to class A. Thus the majority of patients belonged to class B. Child-Pugh class is used in the assessment of patients for liver transplantation and is good indicator of liver disease severity.

MELD score:

In our study, 64 patients (64%) had MELD score greater than 15 and 36 patients (36%) had MELD score less than or equal to 15. MELD

score predicts the prognosis of patients with portal hypertension and liver disease and used for forming the priority list for liver transplant.

CORRELATION BETWEEN SERUM ALBUMIN AND SERUM CHOLINESTERASE

In our study the correlation between serum albumin levels and the levels of serum cholinesterase was studied. It was found that they were positively correlated with a p value <0.01 This was comparable with the observations in the study by Jeyamani Ramachandran et al and Fanping Meng et al.

CORRELATION BETWEEN SERUM BILIRUBIN AND SERUM CHOLINESTERASE

In our study, it was found that the serum bilirubin levels were negatively correlated with serum cholinesterase levels and the p value was <0.01 which was statistically significant. This is similar to the observations made in the study by Jeyamani Ramachandran et al.

CORRELATION BETWEEN INR LEVELS AND SERUM CHOLINESTERASE

In our study, it was found that INR value was negatively correlated with the values of serum cholinesterase and it was statistically significant

with p value <0.01. This was comparable to the observations made in the studies by Jeyamani Ramachandran et al and Fanping Meng et al.

CORRELATION BETWEEN CHILD PUGH CLASS AND SERUM CHOLINESTERASE

In our study, it was found that the serum cholinesterase values were lower in patients with Child Pugh class C and B compared to those with Child Pugh class C. This was found to be statistically significant with a p value <0.01. This was similar to the observations made in the study by Fanping Meng et al and M.H.Sleisenger et al who noted in their study that values of serum cholinesterase were lower among patients with decompensated cirrhosis then patients with compensated cirrhosis .

CORRELATION BETWEEN MELD SCORE AND SERUM CHOLINESTERASE

In our study, it was found that MELD scores were inversely correlated with the seum cholinesterase levels and it was statistically significant with p value <0.01. It was similar to the findings noted by Jeyamani Ramachandran et al.

CONCLUSION

CONCLUSION

From our study, the following results were concluded:

- Liver cirrhosis was more commonly seen among middle aged adults (5 th decade) and is much more common in males with a male to female ratio of 4:1.
- The most commonly observed etiology of cirrhosis was alcohol.
- The most common presenting symptom was ascitis, and the second most common symptom was icterus.
- Among patients with ascitis, majority had ascitis which was mild – moderate (medically controlled).
- Majority of patients in the study did not have hepatic encephalopathy.
- Among patients with hepatic encephalopathy, most patients were in grade II hepatic encephalopathy.
- Majority of patients had splenomegaly either clinically or ultrasonographically, which was indicative of portal hypertension.
- Majority of patients had bilirubin levels greater than 3 mg/dl.
- Most patients in the study did not have coagulopathy, and had INR level <1.7.
- Majority of the patients belonged to Child Pugh class B.
- Most patients had a MELD score greater than 15.

- There was significant positive correlation between serum albumin and serum cholinesterase levels. Patients with a lower serum albumin level also had a lower serum cholinesterase level.
- Significant negative correlation was noted between serum bilirubin and serum cholinesterase levels. Patients with a higher serum bilirubin level had a lower serum cholinesterase level.
- There was significant negative correlation between INR levels and serum cholinesterase levels. Patients in coagulopathy had a lower serum cholinesterase level.
- Significant correlation was found between serum cholinesterase levels and the severity of liver cirrhosis. Its levels were lower in patients with more severe liver disease. Levels were lowest among Child – Pugh class C patients.
- There was significant correlation between serum cholinesterase levels and MELD scores. Patients with a higher MELD score had a lower serum cholinesterase level.

Thus, there was significant correlation between levels of serum cholinesterase and severity of liver cirrhosis.

SUMMARY

SUMMARY

The estimation of serum cholinesterase levels has several implications in the assessment and management of patients with cirrhosis of liver.

Serum cholinesterase activity levels have shown good correlation with the other routinely performed tests of liver function.

Its assessment proves to be even more useful in settings were the commonly performed tests of liver function show abnormal results or altered values secondary to non hepatic causes.

It’s a relatively inexpensive test and can be easily measured on a outpatient basis and among inpatients.

Not only is it useful in the diagnosis, but its value is altered according to the liver disease severity which helps assess prognosis and further management.

Hence, estimation of serum cholinesterase routinely will prove useful in the diagnosis and management of liver cirrhosis.

BIBLIOGRAPHY

BIBLIOGRAPHY

1. Sheila Sherlock, James Dooley; Hepatic Cirrhosis; Diseases Of Liver And Biliary System; Blackwell Science publishers; 11th ed.; pg 368-80.
2. Bruce R Bacon. Cirrhosis and Its Complications; Harrisons Principles of Internal Medicine; 18th ed.;pg 2058-2067
3. Serum-Cholinesterase Activity in Health and in Liver Disease by R.G.O.Kekwick ;Biochem. J. (1960) 76, 420
4. Wilson, A., Calvert, R. J. & Geoghegan, H. (1952). J. clin.Invest. 31, 815.
5. McArdle, B. (1940). Quart. J. Med. 33, 107.
6. Robbins and Cotran .Pathologic Basis of Disease.7 th ED.Liver and Biliary Tract –James M.Crawford.pg 878-888.
7. Schiff's Diseases of the Liver, 10th Edition.Hepatic encephalopathy ch 20 pg 570-575
8. Schiff's Diseases of the Liver, 10th Edition.Hepatic encephalopathy ch 20 pg 579-580
9. Sheila Sherlock, James Dooley; **Chapter 7 Hepatic Encephalopathy** pg 93-95
10. Pulmonary Manifestations of Liver Disease, Michael B. Fallon Miguel R. Arguedas Schiff's Diseases of the Liver, 10th Edition

11. Qamar AA, Grace ND, Groszmann RJ, et al. Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol 2009;7:689.
12. Ellis G, Goldberg DM, Spooner RJ, Ward AM, et al. Serum enzyme tests in diseases of the liver and biliary tree. Am J Clin Pathol 1978; 70:248.
13. Di Lelio A, Cestari C, Lomazzi A, Beretta L, et al. Cirrhosis: diagnosis with sonographic study of the liver surface. Radiology 1989; 172:389.
14. Sanford NL, Walsh P, Matis C, et al. Is ultrasonography useful in the assessment of diffuse parenchymal liver disease? Gastroenterology 1985; 89:186.
15. Bravo AA, Sheth SG, Chopra S, et al. Liver biopsy. N Engl J Med 2001; 344:495.
16. Mendel B, Rudney H. Studies on cholinesterase: 1. Cholinesterase and pseudo-cholinesterase. Biochem J. 1943;37:59–63.
17. Faber M. The relationship between serum cholinesterase and serum albumin. Acta med Scand. 1943;114:72.
18. Kunkel HG, Ward SM. Plasma Esterase Activity in Patients with Liver Disease and the Nephrotic Syndrome. J Exp Med. 1947;86:325–37.

19. Svensmark O. Enzymatic and Molecular Properties of Cholinesterases in Human Liver. Acta Physiol Scand. 1963;59:378–89.
20. Aldrete JA, O'Higgins JW, Holmes J. Changes of plasma cholinesterase activity during orthotopic liver transplantation in man. Transplantation. 1977;23:404–6.
21. Colorimetric Determination Of Serum Cholinesterase:Its Value In Hepatic And Biliary Tract Diseases By M.H.Sleisenger, T.P.Almy, H.Gilder, And G.Perle
22. Kowalski HJ, Abelmmann WH. The cardiac output at rest in Laennecs cirrhosis. J Clin Invest 1953;32:1025-33
23. Orellana Alcalde, J. M., Serum cholinesterase determination in the differential diagnosis of jaundice. J. Lab. & Clin. Med., 1950, 36, 391.
24. Levine, M. G., and Hoyt, R. E., The relationship between human serum cholinesterase and serum albumin. Science, 1950, 111, 286.
25. McCance, R. A., Widdowson, E. M., and Hutchinson, A. O., Effect of undernutrition and alterations in diet on the choline esterase activity of serum. Nature, 1948, 161, 56.
26. Khan MG; The evaluation of serum pseudocholinesterase. Ulster Med J., 1962; 31(2): 144–152

27. Wilson A, Calvert RJ, Geoghegan H; Plasma cholinesterase activity in liver disease: its value as a diagnostic test of liver function compared with flocculation tests and plasma protein determinations. J Clin Invest., 1952; 31(9): 815-823.
28. Hunt AH, Lehmann H. Serum albumin, pseudocholine-sterase, and transaminases in the assessment of liver function before and after venous shunt operations. Gut. 1960;1:303–11.
29. Serum cholinesterase activity in the diagnosis of nonalcoholic fatty liver disease in type 2 diabetic patients; O.O. Ogunkeye , E.K. Chuhwak , A.A.E. Otokwula; Pathophysiology 17 (2010) 29–32
30. Assessment of the value of serum cholinesterase as a liver function test for cirrhotic patients; BIOMEDICAL REPORTS 1: 265-268, 2013; FANPING MENG, XIAOJUAN YIN, XUEMEI MA, XIAO-DONG GUO, BO JIN and HANWEI LI.
31. Sinha SN, Keresztes-Nagy S and Frankfater A: Studies on the distribution of cholinesterases: activity in the human and dog heart. Pediatr Res 10: 754-758, 2006.
32. Davis L, Britten JJ, Morgan M. Cholinesterase. Its significance in anaesthetic practice. Anaesthesia. 1997;52:244–260. doi: 10.1111/j.1365-2044.1997.084-az0080.x.

33. Ostergaard D, Viby-Mogensen J, Hanel HK, Skovgaard LT. Half-life of plasma cholinesterase. Acta Anaesthesiol Scand. 1988;32:266–269. doi: 10.1111/j.1399-6576.1988.tb02727.x.
34. Pan Y, Muzyka JL, Zhan CG. Model of human butyrylcholinesterase tetramer by homology modeling and dynamics simulation. J Phys Chem B. 2009;113:6543–6552. doi: 10.1021/jp8114995.
35. Paes AM, Carniatto SR, Francisco FA, Brito NA, Mathias PC. Acetylcholinesterase activity changes on visceral organs of VMH lesion-induced obese rats. Int J Neurosci. 2006;116:1295–1302. doi: 10.1080/00207450600920910.
36. Cucuianu M, Nistor T, Hâncu N, Orbai P, Muscurel C, Stoian I. Serum cholinesterase activity correlates with serum insulin, C-peptide and free fatty acids levels in patients with type 2 diabetes. Rom J Intern Med. 2002;40:43–51
37. Kutty KM, Payne RH. Serum pseudocholinesterase and very-low-density lipoprotein metabolism. J Clin Lab Anal. 1994;8:247–250. doi: 10.1002/jcla.1860080411.
38. Lampón N, Hermida-Cadahia EF, Riveiro A, Tutor JC. Association between butyrylcholinesterase activity and low-grade systemic inflammation. Ann Hepatol. 2012;11:356–363

39. Rosenman KD, Guss PS. Prevalence of congenital deficiency in serum cholinesterase. Arch Environ Health. 1997;52:42–44. doi: 10.1080/00039899709603798.
40. Dabke AT, Pohowalla JN, Inamdar S, Singh SD, Mathur PS. Serum cholinesterase and histopathology of the liver in severe protein calorie malnutrition. Indian J Pediatr. 1972;39:151–157. doi: 10.1007/BF02750872.
41. Montgomery RD. The relation of oedema to serum protein and pseudocholinesterase levels in the malnourished infant. Arch Dis Childr. 1963;38:343. doi: 10.1136/adc.38.200.343.
42. Butyrylcholinesterase as a prognostic marker: a review of the literature Lidia Santarpia, Ilenia Grandone, Franco Contaldo, and Fabrizio Pasanisi
43. Shan-Zhi G, et al. Alterations of serum cholinesterase in patients with gastric cancer. World J Gastrenterol. 2005;11:4604–4606.
44. Ogunkeye OO, Roluga AI. Serum cholinesterase activity helps to distinguish between liver disease and non liver disease aberration in liver function tests. Pathophysiology. 2006;13:91–93. doi: 10.1016/j.pathophys.2006.01.002.
45. Bozzetti F. Effects of artificial nutrition on the nutritional status of cancer patients. J Parenter Enteral Nutr. 1989;13:406–420. doi: 10.1177/0148607189013004406.

46. Guarnieri G, Faccini L, Lipartiti T, et al. Simple methods for nutritional assessment in hemodialyzed patients. Am. J. Clin. Nutr. 1980;33:1598–1607.
47. Sologub VK, Zaets TL, Tarasov AV, Mordkovitch MR, Yashin AY. Enteral hyperalimentation of burned patients: the possibility of correcting metabolic disorders by the early administration of prolonged high calorie evenly distributed tube feeds. Burns. 1992;18:245–249. doi: 10.1016/0305-4179(92)90080-E.
48. Montagnese C. Cholinesterase and other serum liver enzymes in underweight outpatients with eating disorders. Int J Eat Disord. 2007;40:746–750. doi: 10.1002/eat.20432.
49. Ott M, et al. Intestinal absorption and malnutrition in patients with the acquired immunodeficiency syndrome (AIDS) Gastroenterol Z. 1993;31:661–665.
50. Feldman: Sleisenger & Fordtran's Gastrointestinal and Liver Disease, 8th ed. CHAPTER 70 – Liver Chemistry and Function Tests Aijaz Ahmed Emmet B. Keeffe
51. Friedman LS: The risk of surgery in patients with liver disease. *Hepatology* 1999; 29:1617.
52. Suman A, Barnes DS, Zein NN, et al: Predicting outcome after cardiac surgery in patients with cirrhosis: A comparison of Child-Pugh and MELD scores. *Clin Gastroenterol Hepatol* 2004; 2:719.

53. Freeman Jr RB: MELD and liver allocation: Continuous quality improvement. *Hepatology* 2004; 40:787.

54. Malinchoc M, Kamath PS, Gordon FD, et al: A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. *Hepatology* 2000; 31:864.

55. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48:835-847.

56. Coco B, Oliveri F, Maina AM, et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat. 2007;14:360-369.

57. Bensamoun SF, Wang L, Robert L, et al. Measurement of liver stiffness with two imaging techniques: magnetic resonance elastography and ultrasound elastography. J Magn Reson Imaging. 2008;28:1287-1292.

58. Castera L, Le Bail B, Roudot-Thoraval F, et al. Early detection in routine clinical practice of cirrhosis and esophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. J Hepatol. 2009;50:59-68.

59. Ganne-Carrie N, Ziol M, de Ledinghen V, et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology. 2006;44:1511-1517

60. Millonig G, Reimann FM, Friedrich S, et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology. 2008;48:1718-1723.
61. Sagir A, Erhardt A, Schmitt M, et al. Transient elastography in unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology. 2008;47:592-595.
62. Albers I, Hartmann H, Bircher J, et al: Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. *Scand J Gastroenterol* 1989; 24:269.
63. Burra P, Masier A: Dynamic tests to study liver function. *Eur Rev Med Pharmacol Sci* 2004; 8:19.
64. Kuo PC, Johnson LB, Plotkin JS, Howell CD, Bartlett ST, Rubin LJ. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997;63:604-6
65. Higenbottam T, Wheeldon D, Wells F, et al .Long term treatment of primary pulmonary hypertension with continuous intravenous epoprostenal prostacyclin) Lancet 1984;1:1046-7.
66. Higenbottam T, Spiegelhatler D, Scott, et al. Prostacyclin (epoprostenol) and heart –lung transplantation as treatments for severe pulmonary hypertension. Br Heart J 1993;70:336-70.

67. Halank M, Miehlke S, Hoeffken G,et al. Use of oral endothelin receptor antagonist bosentan in the treatment of portopulmonary hypertension, Transplantation 2004;77:1775-6.
68. Hinterhuber L, Graziadei IW, Kahler CM, et al. Endothelin receptor antagonist treatment of portopulmonary hypertension Clin gastroenterol Hepatol 2004;2:1039-42.
69. Reichengerger F, Voswinckel R, Steveling E, Enke B, Kreckel A, Olschewski H, *et al*. Sildenafil treatment for portopulmonary hypertension. Eur Respir J 2006;28:563-7
70. Porres-Aguilar M, Zuckerman MJ, Figueroa-Casas JB, Krowka MJ. Portopulmonary hypertension: State of the art. Ann Hepatol 2008;7:321-30.
71. Agnelli G, Parise P, Levi M, et al: Effects of desmopressin on hemostasis in patients with liver cirrhosis. *Haemostasis* 1995; 25:241.
72. Mammen EF: Coagulation defects in liver disease. *Med Clin North Am* 1994; 78:545.
73. Biopsy of the liver; ch 3; pg 37-46; Sheila Sherlock, James Dooley; Hepatic Cirrhosis; Diseases Of Liver And Biliary System; Blackwell Science publishers; 11th ed.

ANNEXURES

PROFORMA

PATIENT DETAILS:

Name: Age: Sex:

IP No. :

ON ADMISSION:

Main Complaints :

- H/o jaundice
- H/o abdominal distension
- H/o pedal oedema
- H/o reduced urine output
- H/o breathlessness
- H/o orthopnoea/PND
- H/o haemetemesis
- H/o melena
- H/o seizures
- H/o altered sensorium
- H/o altered sleep pattern
- H/o chest pain
- H/o abdominal pain
- H/o fever
- H/o constipation
- H/o intake of any drugs

Co – Morbid Illness :

Significant Past History :

CLINICAL EXAMINATION:

Pulse	:	BP :	
RR	:	Temp :	
Pallor	:	Icterus :	
CVS	:	RS :	
P/A	:		
CNS	:		

INVESTIGATIONS :

Hemogram	:
Renal Function Test	:
BT/CT/PT/INR	:
Blood Grouping	:
Serum cholinesterase	:
ECG	:
CXR	:
USG Abdomen	:
LFT	:

ஆராய்ச்சியில் பங்கேற்பவர்கான தகவல் அறிக்கை

ஆராய்ச்சியின் தலைப்பு : கல்லீரல் இழைநார் வளர்ச்சி கண்டறிய குருதிச்சீரத்தில் கோலினெஸ்டெரேஸ் எனும் என்சைம்மின் அளவை கணக்கிடுவதின் பயன் பற்றிய ஆராய்ச்சி.

பங்குகொள்வரின் பெயர் :
ஆராய்ச்சி செய்பவரின் பெயர் : சுஜாதா நா.
இடம் : ராஜீவ் காந்தி அரசு பொது மருத்துவமனை, சென்னை – 600003

இந்த ஆராய்ச்சி / ஆய்வு / செய்முறை / சோதனையில் தாங்கள் பங்கேற்க அழைக்கிறோம். இந்த தகவல் அறிக்கையில் கூறப்பட்டிருக்கும் தகவல்கள் தாங்கள் இந்த ஆராய்ச்சியில் பங்கேற்கேலமா வேண்டாமா என்பதை முடிவு செய்ய உதவியாக இருக்கும். இந்த படிவத்தில் உள்ள தகவல்கள் பற்றி உள்ள சந்தேகங்களை நீங்கள் தயங்காமல் கேட்கலாம்.

இந்த ஆய்வின் நோக்கம் என்ன?

கல்லீரல் இழைநார் வளர்ச்சி கண்டறிய குருதிச்சீரத்தில் கோலினெஸ்டெரேஸ் எனும் என்சைம்மின் அளவை கணக்கிடுவதின் பலாபலன் பற்றிய ஆராய்ச்சி.

ஆய்வு முறைகள் :

விரிவான நோய்க் குறிப்புகளும் மருத்துவ பரிசோதனைகளும் செய்யப்படும். நோயாளிகள், அவர்கள் சம்மதத்திற்கு பின் குருதிச்சீரத்தில் கோலினெஸ்டெரேஸ் எனும் என்சைம்மின் அளவு கணக்கிடப்படும்

ஆய்வினால் மக்களுக்கு ஏற்படும் நன்மைகள் :

இந்த ஆய்வின் முடிவில் கிடைக்கும் தகவல்கள் சமுதாயதிற்கு பயனுள்ளதாகவும், எதிர்காலத்தில் நோயாளிகளுக்கு மருத்துவ தீர்வாகவும் அமையும்.

தங்களிடமிருந்து பெறப்படும் தகவல்களின் நம்பிகத்தன்மை :

தங்களிடமிருந்து பெறப்படும் தகவல்கள் பாதுகாக்கப்படுவதற்கான முழு உரிமையும் தங்களுக்கு உண்டு.

இந்த படிவத்தில் கையொப்பமிடுவதன் மூலம், தாங்கள் தங்களை பற்றிய விவரங்களையும், ஆய்வு விவரங்களையும் ஆராய்ச்சியாளர், ஆய்வு நடத்தும் ஏனையோர் வரைமுறை ஒழுங்கு குழுவினர் மற்றும் சட்டத்திற்கு உட்பட்ட மருந்து கட்டுப்பாடு இயக்குநனர் ஆகியோர் பார்வையிட அனுமதிக்கின்றீர்கள்.

இந்த ஆய்வில் காட்டப்படும் தகவல்கள் அறிவியல் நாளேடுகளிலோ அறிவியல் கூட்டங்களிலோ சமர்ப்பிக்கப்படும் பட்சத்தில் தங்களது அடையாளம் வெளிப்படுத்தப்படமாட்டாது.

இந்த ஆய்வில் பங்கேற்காமல் இருப்பதனால் ஏற்படும் பாதிப்பு:

இந்த ஆய்வில் தாங்கள் பங்கேற்க விருப்பம் தெரிவிக்காத நிலையில் தங்களின் மருத்துவர் மற்றும் மருத்துவமனையில் தங்களுக்கு உள்ள உறவில் எந்த பாதிப்பும் ஏற்படாது. தாங்கள் சிறப்பாக கவனிக்கப்படுவீர்கள். மேலும் இதனால் தங்களுக்கு இழப்பு ஏதும் ஏற்படாது.

ஆய்வின் நடுவில் அதிலிருந்து விலகிக் கொள்ள நினைத்தால்:

இந்த ஆய்வில் பங்கேற்பது தங்களின் சொந்த விருப்பமே. மேலும் ஆய்வின் நடுவில் எந்த நேரத்திலும், எக்காரணமும் கூறாமல் விலகிக்கொள்ள தங்களுக்கு முழு உரிமையும் உண்டு. இருப்பினும் ஆய்விலிருந்து விலகுவதற்கு முன் ஆராய்ச்சி குழுவுடன் கலந்து ஆலோசிப்பது உகந்தது என பரிந்துரைக்கப்படுகின்றது.

ஆராய்ச்சியாளர் கையொப்பம்
தேதி:

பங்கேற்பவரின் கையொப்பம்
தேதி:

INFORMATION SHEET

We are conducting a study on **"A STUDY ON SERUM CHOLINESTERASE AS A BIOMARKER OF LIVER CIRRHOSIS"** among patients attending Rajiv Gandhi Government General Hospital, Chennai and for that your specimen may be valuable to us.

The purpose of this study is

1. To estimate the level of serum cholinesterase in patients with liver cirrhosis.

2. To compare its level with other tests of liver function like bilirubin, SGOT,SGPT,PT INR,ALP and MELD Score.

We are selecting certain cases and if you are found eligible, we may be using your information which in any way do not affect your final report or management.

The privacy of the patients in the research will be maintained throughout the study. In the event of any publication or presentation resulting from the research, no personally identifiable information will be shared.

Taking part in this study is voluntary. You are free to decide whether to participate in this study or to withdraw at any time; your decision will not result in any loss of benefits to which you are otherwise entitled.

The results of the special study may be intimated to you at the end of the study period or during the study if anything is found abnormal which may aid in the management or treatment.

Signature of Investigator Signature of Participant

Date:
Place:

ஆராய்ச்சி ஒப்புதல் படிவம்

ஆராய்ச்சியின் தலைப்பு : கல்லீரல் இழைநார் வளர்ச்சி கண்டறிய குருதிச்சீரத்தில் கோலினெஸ்டெரேஸ் எனும் என்சைம்மின் அளவை கணக்கிடுவதின் பயன் பற்றிய ஆராய்ச்சி..

ஆராய்ச்சி செய்பவரின் பெயர் : சுஜாதா நா.
ஆராய்ச்சி மையம்: ராஜீவ் காந்தி அரசு பொது மருத்துவமனை,
சென்னை – 600003

_____ எனும் நான், எனக்கு கொடுத்துள்ள தகவல் தாளை படித்து புரிந்து கொண்டேன். நான் பதினெட்டு வயதை கடந்துள்ளதால், என்னுடைய சுயநினைவுடனும், முழு சுகந்திரதுடனும், இந்த ஆராய்ச்சியில் என்னை சேர்த்துக்கொள்ள சம்மதிக்கிறேன்.

1. நான் எனக்கு அளிக்கப்பட்ட ஒப்புதல் படிவத்தையும், தகவல்களையும் படித்து புரிந்து கொண்டேன்.
2. ஒப்புதல் படிவத்தில் உள்ள தகவல்கள் எனக்கு விளக்கிக் கூறப்பட்டன
3. ஆய்வின் தன்மை பற்றி எனக்கு விளக்கப்பட்டது
4. என்னுடைய உரிமைகளையும், பொறுப்புகளையும் ஆராய்ச்சியாளர் விளக்கிக் கூறினார்.
5. நான் இதுவரை எடுத்துள்ள/ எடுத்து கொண்டிருக்கும் அணைத்து விதமான சிகிச்சை முறைகளையும் ஆராய்ச்சியாளரிடம் கூறியுள்ளேன்.
6. இந்த ஆராய்ச்சியினால் ஏற்படும் தீமைகள் பற்றி விளக்கப்பட்டன.

7. நான் ஆராய்ச்சியாளருடன் ஒத்துழைப்பேன் என்றும் எனக்கு ஏற்படக்கூடிய அசாதாரணமான நிகழ்வுகள் பற்றியும் உடனடியாக ஆராய்ச்சியாளரிடம் தெரிவிப்பேன் என்று உறுதி கூறுகிறேன்.

8. நான் கடந்த ..... மாதங்களாக வேறு எந்தவிதமான ஆய்வுகளிலும் பங்கேற்கவில்லை.

9. எனக்கு செய்யப்படும் அனைத்து பரிசோதனைகளும் (உதாரணம்: இரத்தம் எடுத்தல்) என் நோயின் தன்மையை அறிவதற்காக செய்யப்படுபவை என்பதை அறிகிறேன்.

10. இந்த ஆய்விலிருந்து எப்போது வேண்டுமானாலும் எக்காரணமும் கூறாமல் என்னை விடுவித்துக் கொள்ளலாம் என்பதை அறிவேன். மற்றும் இதனால் எனக்குத் தரப்படும் சிகிச்சைக்கு எந்த பாதிப்பும் வராது என்பதை அறிவேன்.

11. ஆராய்ச்சியாளர்கள் இந்த ஆய்வில் எனது பங்களிப்பை எந்த நேரத்திலும், எக்காரணமும் கூறாமல் என் சம்மதம் இல்லாமலும் என்னை விலக்கிவிட முடியும் என்பதை அறிவேன்.

12. என்னிடம் இருந்து பெறப்படும் தகவல்களை அரசு, வரைமுறை அதிகாரிகள் ஆகியோர்களுடன் பகிர்ந்து கொள்ள ஆராய்ச்சியாளர்களுக்கு அனுமதி அளிக்கிறேன். என்னுடைய தஸ்தாவேஜீகளை பார்வையிட அவர்களுக்கு உரிமை உண்டு.

13. என்னிடம் பெறப்படும் தகவல்கள் பொதுவாக பிரசுரிக்கப்பட்டால், என்னுடைய அடையாளம் இரகசியமாக வைக்கப்படும் என்பதை அறிவேன்.

14. எனக்கு திருப்தியளிக்கும் வகையில் எனக்குக் கேட்கப்பட்ட கேள்விகளுக்கு பதில் அளிக்கப்பட்டது.

15. இந்த ஆராய்ச்சியில் பங்கேற்க தன்னிச்சையாக முழுமனதுடன் நான் சம்மதிக்கிறேன்.

இந்த ஆய்வின் போது எனக்கு என்ன சந்தேகம் ஏற்பட்டாலும் ஆராய்ச்சியாளரை தொடர்பு கொள்ளலாம் என்பதை அறிவேன். இந்த ஒப்புதல் படிவத்தில்

கையெழுத்திடுவது மூலம் இங்கு தரப்பட்டிருக்கும் அனைத்து தகவல்களும் தெளிவாகக் கூறப்பட்டு என்னால் முழுமையாக புரிந்துக் கொள்ளப்பட்டது என்பதை சான்றளிக்கிறேன். இந்த ஒப்புதல் படிவத்தின் நகல் என்னால் பெற்றுக் கொள்ளப்பட்டது.

பங்கேற்பவரின் கையொப்பம்: இடம்:

கட்டைவிரல் ரேகை: தேதி:

பங்கேற்பவரின் பெயர்:

விலாசம்:

ஆய்வாளரின் பெயர் : இடம்:

ஆய்வாளரின் பெயர் : தேதி:

PATIENT CONSENT FORM

Study Details : "**A STUDY ON SERUM CHOLINESTERASE AS A BIOMARKER OF LIVER CIRRHOSIS"**

Study Centre : **RAJIV GANDHI GOVERNMENT GENERAL HOSPITAL, CHENNAI**.

Patient's Name:

Patient's Age:

In Patient Number:

Patient may check (☑) these boxes

I confirm that I have understood the purpose of procedure for the above study. I have the opportunity to ask question and all my questions and doubts have been answered to my complete satisfaction. ❑

I understand that my participation in the study is voluntary and that I am free to withdraw at any time without giving reason, without my legal rights being affected. ❑

I understand that sponsor of the clinical study, others working on the sponsor's behalf, the ethical committee and the regulatory authorities will not need my permission to look at my health records, both in respect of current study and any further research that may be conducted in relation to it, even if I withdraw from the study I agree to this access. However, I understand that my identity will not be revealed in any information released to third parties or published, unless as required under the law. I agree not to restrict the use of any data or results that arise from this study. ❑

I agree to take part in the above study and to comply with the instructions given during the study and faithfully cooperate with the study team and to immediately inform the study staff if I suffer from any deterioration in my health or well being or any unexpected or unusual symptoms. ❑

I hereby consent to participate in this study ❑

I hereby give permission to undergo complete clinical examination and diagnostic tests including hematological, biochemical, radiological tests. ❑

Signature/Thumb Impression

Patient's Name & Address:

Signature of Investigator

Study Investigator's Name:
Dr.SUJATHA.N.

INSTITUTIONAL ETHICS COMMITTEE
MADRAS MEDICAL COLLEGE, CHENNAI-3

EC Reg No.ECR/270/Inst./TN/2013
Telephone No. 044 25305301
Fax : 044 25363970

CERTIFICATE OF APPROVAL

To
Dr.Sujatha N
Post Graduate M.D.(General Medicine)
Madras Medical College
Chennai 600 003

Dear Dr.Sujatha N,

The Institutional Ethics Committee has considered your request and approved your study titled **"A study on serum cholinesterase as a biomarker of liver cirrhosis" No.03052015.**

The following members of Ethics Committee were present in the meeting held on 12.05.2015 conducted at Madras Medical College, Chennai-3.

1. Prof.C.Rajendran, M.D.,	: Chairperson
2. Prof.R.Vimala, M.D., Dean, MMC, Ch-3	: Deputy Chairperson
3. Prof.B.Kalaiselvi, M.D., Vice-Principal, MMC, Ch-3	: Member Secretary
4. Prof.B.Vasanthi, M.D., Prof. of Pharmacology, MMC	: Member
5. Prof.P.Ragumani, M.S., Professor of Surgery, MMC	: Member
6. Prof.Saraswathy, M.D., Director, Pathology, MMC, Ch-3	: Member
7. Prof.K.Srinivasagalu, M.D.,Director, I.I.M. MMC, Ch-3	: Member
8. Thiru S.Rameshkumar, B.Com., MBA	: Lay Person
9. Thiru S.Govindasamy, B.A., B.L.,	: Lawyer
10. Tmt.Arnold Saulina, M.A., MSW.,	: Social Scientist

We approve the proposal to be conducted in its presented form.

The Institutional Ethics Committee expects to be informed about the progress of the study and SAE occurring in the course of the study, any changes in the protocol and patients information/informed consent and asks to be provided a copy of the final report.

Member Secretary, Ethics Committee

MEMBER SECRETARY
INSTITUTIONAL ETHICS COMMITTEE
MADRAS MEDICAL COLLEGE

MASTER CHART

S.No.	Age	Sex	Alcohol intake	Icterus	Ascitis	Hepatic Encephalopathy	Serum Bilirubin	Serum Albumin	Serum Creatinine	PT/INR	Viral Markers	Ultrasound Abdomen	Child Pugh Class	MELD Score	Serum Cholinesterase
1	44	M	+	+	++	Gr II	8.7	3.3	1.5	32/2.98	HbSAg +ve	Ci+As+S	C	31	1967
2	47	M	+	+	+	-	11.4	3	0.5	13.2/1.18	HbSAg +ve	Ci+As+S	B	17	3125
3	33	M	+	+	+	-	5.2	3.2	0.7	20.7/1.8	-	Ci+As	C	19	2242
4	50	M	+	+	+	Gr I	3.3	3	2.8	29.6/2.51	-	Ci+As+S	C	31	1356
5	45	F	-	-	+	-	1	3	1.5	14.2/1.31	-	Ci+As+S	B	13	4372
6	45	M	+	+	++	Gr I	28.3	2.8	1.7	25.2/2.16	HbSAg +ve	Ci+As+S	C	33	1635
7	38	M	+	+	+	-	11.5	3.5	1.3	30.2/2.56	-	Ci+As+S	C	29	1435
8	40	M	+	+	+	Gr I	17.5	2.9	0.6	21.3/1.89	HCV +ve	Ci+As+S	C	24	1532
9	42	M	-	-	+	Gr III	10.6	2.2	1.1	19.3/1.45	HCV +ve	Ci+As+S	C	20	1634
10	60	M	+	+	+	Gr I	5.6	2.6	1.6	24.1/2.07	-	Ci+As+S	C	26	1463
11	55	F	-	-	+	-	1.8	1.8	1.3	13.8/1.3	-	Ci+As+S	B	14	2131
12	55	F	-	-	+	-	0.4	2.7	0.7	13.7/1.23	-	Ci+As	B	9	4800
13	55	M	+	+	+	Gr I	8.9	2	1.2	13.4/1.14	-	Ci+As	C	18	2131
14	52	M	+	+	+	-	3.2	3	0.5	13.7/1.16	-	Ci+As	B	12	4363
15	52	M	+	+	+	-	3.8	2.5	0.9	29.8/2.53	-	Ci+As+S	C	22	1962
16	36	M	+	-	-	-	1.7	3.6	0.8	11.2/1	-	Ci	A	8	6101
17	28	M	+	-	+	-	2.9	2.9	1.4	13.6/1.2	-	Ci+As+S	B	16	2963
18	33	M	+	+	+	Gr III	16	3.2	1.1	25.3/2.1	-	Ci+As+S	C	26	2243
19	27	M	+	-	-	-	1.8	3.3	0.5	11.5/1.0	-	Ci	A	9	5125
20	45	M	+	+	+	-	5	3.6	1.7	12.6/1.1	-	Ci+As+S	B	19	2563
21	45	M	+	+	-	-	11	3.1	1	25.3/2.2	-	Ci+S	B	24	2869
22	56	M	+	-	+	-	2.8	2.9	1.6	11.2/1	-	Ci+As	B	15	3100
23	70	M	-	+	++	-	12.4	3.1	1.3	13.8/1.3	HbSAg +ve	Ci+As+S	C	21	2649
24	43	M	+	-	-	-	2.7	3.8	0.6	13.9/1.2	-	Ci	A	12	3964
25	44	F	-	+	+	Gr I	7.5	2.6	1.1	13.7/1.2	HbSAg +ve	Ci+As+S	C	17	2436
26	29	M	+	+	+	-	6.3	3	0.9	11.5/1	-	Ci+As	B	13	4396
27	46	F	-	+	+	-	8	3.1	0.8	13.6/1.2	HbSAg +ve	Ci+As+S	B	16	2865
28	57	M	+	+	++	Gr II	5.8	3.4	1.3	25.7/2.2	-	Ci+As+S	C	24	1934
29	63	M	+	+	+	-	6.7	3.6	1.1	26.4/2.2	-	Ci+As+S	B	23	1923
30	49	M	-	+	-	-	3	3.6	0.5	14.16/1.2	-	Ci+S	A	13	5318
31	35	M	+	+	+	-	8.6	3.2	1.3	12.5/1	-	Ci+As+S	B	17	2676
32	46	M	-	+	+	-	9.4	3.1	1.1	11.6/1	-	Ci+As	B	16	2789
33	53	M	+	+	++	Gr II	12.6	2.9	0.9	13.7/1.2	-	Ci+As+S	C	18	2345
34	55	F	-	+	-	-	5.4	3.2	1.1	25/2.1	-	Ci+S	B	22	1852
35	34	M	+	-	-	-	2.3	3.6	0.9	13.8/1.2	-	Ci	A	12	5232
36	60	M	+	+	+	-	6.3	3.3	1.5	11.4/1	-	Ci+As	B	17	2345
37	57	M	+	+	+	-	7.3	3.2	1.2	12.3/1.1	-	Ci+As	B	17	2652
38	45	M	+	+	++	Gr III	10.3	2.8	1.4	28/2.5	-	Ci+As+S	C	29	1754
39	38	M	+	+	+	-	4.2	3.6	1.1	12.5/1	-	Ci+As	B	13	4312
40	41	F	-	-	+	-	1.7	3.6	0.6	18.4/1.6	HbSAg +ve	Ci	A	14	5324

41	33	M	+	+	+	-	6.3	3.4	0.9	14.5/1.3	-	Ci+As+S	B	16	2489
42	39	M	+	+	+	Gr III	10.5	3.3	1.1	11.8/1.1	-	Ci+As+S	C	17	1237
43	46	M	+	+	+	-	8.5	3.2	1.3	12.4/1.1	-	Ci+As+S	B	18	2229
44	29	M	+	-	-	-	1.4	3.8	0.7	23.2/2	-	Ci	A	15	4296
45	47	M	-	+	+	Gr II	8	3.6	1.1	25.2/2.16	-	Ci+As+S	C	24	1437
46	36	M	-	+	+	-	6	3.2	1.5	11.8/1.1	HbSAg +ve	Ci+As+S	B	18	2134
47	38	M	+	+	+	-	7.6	3.4	1	12.7/1.2	-	Ci+As	B	16	2735
48	47	F	-	-	+	-	1.8	3.6	0.6	17.25/1.5	-	Ci+As	A	13	4376
49	37	M	+	+	+	-	5.7	3.2	0.7	13.8/1.3	-	Ci+As+S	B	16	2536
50	35	M	+	-	+	-	1.9	3.7	0.7	12.76/1.1	-	Ci	A	10	5103
51	49	F	-	+	-	-	4.3	3.2	0.6	12.6/1.1	-	Ci+S	B	13	3963
52	48	M	+	+	++	Gr II	12	3.4	0.9	23.5/2	-	Ci+As+S	C	24	1869
53	60	F	+	+	+	-	10	3.1	0.6	14/1.2	-	Ci+S	B	17	2106
54	54	M	+	+	+	Gr III	13.6	2.8	1.4	25.7/2.2	-	Ci+As+S	C	28	1684
55	36	M	+	-	-	-	2.3	3.6	1	11.6/1	-	Ci+S	A	10	5132
56	47	F	-	+	+	-	6.3	3.4	0.9	11.5/1.1	HCV+ve	Ci+As	B	14	2753
57	38	M	+	+	++	Gr II	6.5	2.9	0.8	18.9/1.7	-	Ci+As+S	C	19	1437
58	47	M	+	+	+	-	7.5	3.2	1.1	15/1.2	HCV+ve	Ci+As+S	B	18	1988
59	39	M	-	+	+	-	6.1	3.4	1	14/1.1	-	Ci+As	B	14	2768
60	57	M	+	-	-	-	2.9	3.6	0.9	11.5/1	-	Ci+S	A	10	4239
61	34	M	+	+	+	-	7.1	3.2	0.8	11.7/1.2	-	Ci+As+S	B	16	2346
62	36	M	+	-	+	-	1.8	3.6	0.7	12.7/1.1	-	Ci+As+S	A	10	5234
63	45	M	+	+	+	Gr II	5.8	3.1	1.1	21/1.9	-	Ci+As+S	C	21	1534
64	42	M	+	+	+	-	8.2	3.4	1.2	11.6/1.1	-	Ci+As	B	17	2238
65	31	M	+	-	+	-	1.9	3.6	0.9	11.7/1	-	Ci+As	A	9	4201
66	43	M	-	+	+	Gr II	11.3	2.9	1.3	26/2.2	-	Ci+As+S	C	27	1932
67	46	M	+	+	+	-	10.3	3.2	1.1	14/1.2	-	Ci+As+S	B	18	2121
68	43	M	+	-	+	-	1.8	3.8	0.5	13.8/1.2	-	Ci+As+S	A	11	4003
69	52	M	+	+	+	-	6.4	3.1	1	13/1.3	-	Ci+As	B	16	2459
70	37	M	+	+	+	Gr I	11.2	3.2	0.9	23.5/2	-	Ci+As+S	C	23	2101
71	47	F	-	-	-	-	2.9	3.6	0.8	11.5/1.1	-	Ci	A	12	4126
72	70	M	+	+	+	-	6.5	3.3	1.1	11.4/1	-	Ci+As	B	14	2963
73	62	F	-	+	+	Gr II	13.2	3.1	1.1	19/1.6	-	Ci+As+S	C	22	2411
74	46	M	+	+	-	-	3	3.7	0.8	11.7/1.1	-	Ci	A	12	3925
75	53	F	-	+	+	-	7.2	3.3	0.9	12.5/1.2	-	Ci+As	B	16	2452
76	29	M	+	-	+	-	1.8	3.7	0.8	11.3/1	-	Ci+As	A	9	3845
77	32	M	+	+	+	Gr III	10.2	2.9	1.1	24/2.1	-	Ci+As+S	C	24	2430
78	47	M	+	+	+	-	7.6	3.1	1.2	12.1/1	-	Ci+As	B	16	2639
79	43	M	+	-	+	-	1.5	3.6	0.5	16.5/1.5	-	Ci+S	A	13	4631
80	35	M	+	+	++	Gr IV	10.3	2.9	1.6	26/2.3	-	Ci+As+S	C	29	1943

81	21	M	+	+	+	-	6.4	3.2	1.1	13.5/1.2	-	Ci+As+S	B	16	2766
82	43	M	+	-	-	-	2.8	3.6	0.9	12.7/1.1	-	Ci	A	11	4765
83	36	M	+	+	+	-	8.7	3.1	1	12.8/1.1	-	Ci+As+S	B	16	2836
84	38	F	-	-	+	-	1.9	3.6	0.7	11.4/1	-	Ci+As+S	A	9	4396
85	62	F	-	+	++	Gr II	4.5	3	0.9	19/1.6	HbSAg +ve	Ci+As+S	C	17	1923
86	50	M	+	+	+	-	11.5	3.3	1.2	16.3/1.4	-	Ci+As	B	21	1981
87	46	M	+	+	+	-	6.3	3.4	1.1	11.8/1.2	-	Ci+As+S	B	16	2896
88	47	F	-	+	+	-	5.4	3.1	0.8	11.6/1.1	-	Ci+As+S	B	14	2439
89	34	M	+	-	-	-	1.2	3.4	0.8	16.5/1.5	-	Ci+S	A	12	4357
90	37	M	-	+	++	Gr II	14	2.9	1.6	20.1/1.7	-	Ci+As+S	C	27	1845
91	32	M	+	+	++	Gr I	13	2.9	1.2	11.6/1.01	-	Ci+As+S	C	18	2348
92	46	M	+	-	+	-	1.8	3.6	0.7	17.8/1.4	-	Ci+As+S	A	12	5348
93	41	M	+	+	+	Gr II	16	3.2	1.1	16.3/1.4	-	Ci+As+S	C	22	1863
94	46	F	-	-	-	-	2.3	3.6	0.8	11.4/1	-	Ci	A	10	4638
95	43	M	+	+	++	Gr III	10.6	3.4	1.6	28.3/2.4	-	Ci+As+S	C	30	1654
96	55	F	+	+	+	Gr I	12.4	3.2	1.1	11.5/1	-	Ci+As	C	17	1932
97	32	M	+	+	+	Gr I	16	3.2	1.1	17/1.5	-	Ci+As+S	C	22	2163
98	36	M	+	-	-	-	2.8	3.6	0.7	12.8/1.1	-	Ci	A	11	4935
99	61	F	-	+	+	Gr II	11.4	2.9	1.4	21.8/1.8	-	Ci+As+S	C	25	1763
100	42	M	+	+	+	-	10.5	3.1	1	19.2/1.6	-	Ci+As	B	21	2034

M- Male; F-Female; Under Ascitis: + mild moderate, ++ severe ascitis; Gr-Grade

Ci- Cirrhosis; As-Ascitis; S- Splenomegaly; PT INR- Prothrombin Time/International Normalised Ratio; MELD-Model for End stage Liver Disease;

turnitin

Digital Receipt

This receipt acknowledges that Turnitin received your paper. Below you will find the receipt information regarding your submission.

The first page of your submissions is displayed below.

Submission author:	201311020.md General Medicine SU.
Assignment title:	TNMGRMU EXAMINATIONS
Submission title:	SERUM CHOLINESTERASE AS A B...
File name:	22092015Thesis.docx
File size:	6.75M
Page count:	101
Word count:	7,280
Character count:	43,560
Submission date:	23-Sep-2015 11:02PM
Submission ID:	574530993



INTRODUCTION


Turnitin Document Viewer - Mozilla Firefox
https://www.turnitin.com/dv?o=574530693&u=1043621752&s=&student user=1&lang=en us
The Tamil Nadu Dr.M.G.R.Medical U...
TNMGRMU EXAMINATIONS - DUE 30-Oc..
Originality
GradeMark
PeerMark
SERUM CHOLINESTERASE AS A BIOMARKER OF LIVER CIRRHOSIS
BY 261311020.MD GENERAL MEDICINE SUJATHA.N
turnitin
6%
SIMILAR
--
OUT OF 0
1
INTRODUCTION
Match Overview
1 "AASLD Abstracts", He... Publication 1%
2 www.thermofinnigan.fr Internet source 1%
3 A CARDENAS. "Ascite... Publication 1%
4 Li, Hanwei. "Assessme... Publication <1%
5 K. Pratibha. "Serum ad... Publication <1%
6 B TENNANT. "Hepatic... Publication <1%
7 Gin-Ho Lo. "A controlle... Publication <1%
8 "Abstract Index", Journ... Publication <1%
9 www.beltina.org Internet source <1%
10 "Posters", Liver Interna... Publication <1%
PAGE: 1 OF 101
Text-Only Report
23:19
23-09-2015